Business Overview: Standard BioTools Inc. (NASDAQ: LAB)

---

Executive Summary

Standard BioTools Inc. makes instruments, consumables, and services for early discovery, translational, and clinical life-science research. Incorporated in California in 1999 as Mycometrix Corporation, it became Fluidigm Corporation in 2001 and was renamed Standard BioTools Inc. on April 1, 2022. The company describes the annual worldwide life-sciences research tools total addressable market at more than $70 billion.

In a major 2025/2026 portfolio move, Standard BioTools sold its SomaScan aptamer-based proteomics business to Illumina (signed June 22, 2025; closed January 30, 2026), narrowing its focus back to its core mass cytometry and microfluidics platforms. International sales remain significant — 67% of 2025 revenue ($56.9 million) came from outside the United States.

---

1. Core Business Model & How They Work

[ Instrument Sale/Placement (CyTOF, Hyperion, Biomark X9) ] ➡️ [ Recurring Consumables (metal-tagged antibody panels, reagents) ] ➡️ [ Services & Support ]

Key Operational Drivers

1. Razor/razorblade instrument model: capital equipment sales (mass cytometers, imaging systems, microfluidic qPCR systems) create an installed base that then consumes recurring, proprietary reagents and consumables.
2. Portfolio focus via divestiture: selling SomaScan to Illumina concentrates the company on its two core technology platforms rather than spreading R&D and sales resources across three.
3. Deep IP licensing base: core mass cytometry technology traces back to licensed patents from Caltech, Harvard University, and Caliper Life Sciences (now part of PerkinElmer), including mass cytometry patents purchased from PerkinElmer in 2015 for $6.5 million.

---

2. Business Segments

Following the SomaScan divestiture, Standard BioTools operates its continuing business as a single life-science tools segment built around two core platforms (mass cytometry and microfluidics); SomaScan is now reported as discontinued operations.

---

3. Product Portfolio

---

4. Competitive Landscape

• Genomics/broad life-science tools: Agilent Technologies, Thermo Fisher Scientific, Bio-Rad Laboratories, and Mesa Laboratories — all dramatically larger, diversified life-science tools companies.
• Flow cytometry: Cytek Biosciences and Becton, Dickinson and Company (BD) — direct competitors in cell-analysis instrumentation, an adjacent technology to mass cytometry.
• Spatial biology: NanoString Technologies and 10x Genomics — direct competitors in the specific high-plex spatial/imaging niche where Hyperion competes.
• The company also notes 10 to 20 smaller competitors, underscoring a genuinely fragmented, crowded space at the margins even though the named competitors above are the dominant forces.

---

5. Strategic Strengths & Risks

Strengths

• Substantial patent estate: approximately 400 owned or licensed patents plus roughly 150 pending applications worldwide as of December 31, 2025, with some utility/design patents running as late as 2047.
• Differentiated core technology: metal-tagged antibody mass cytometry (CyTOF/Hyperion) is a genuinely distinct approach from fluorescence-based flow cytometry, giving Standard BioTools a technical niche rather than a commodity instrument position.
• Sharpened strategic focus post-SomaScan divestiture, concentrating resources on two platforms rather than three.
• Meaningful international diversification: 67% of revenue from outside the US reduces dependence on any single geographic research-funding environment.

Risks

• Scale disadvantage: competing against Thermo Fisher, Agilent, Bio-Rad, and BD — all vastly larger, better-resourced companies that can bundle competing technologies into broader product catalogs.
• Key patent expirations approaching: the last of the PerkinElmer-acquired mass cytometry patents is expected to expire in November 2026, a near-term IP cliff worth monitoring.
• Crowded spatial biology niche: 10x Genomics and NanoString are both well-funded, fast-moving competitors in the specific high-plex spatial analysis category Hyperion targets.
• Post-divestiture execution risk: successfully refocusing commercial and R&D resources on two platforms after shedding SomaScan is a real near-term operational challenge.

---

6. Financial Overview

---

7. Summary Conclusion

Standard BioTools has refocused around a genuinely differentiated core technology — metal-tagged mass cytometry (CyTOF/Hyperion) — after divesting its SomaScan proteomics business to Illumina, concentrating its patent estate and commercial resources on two platforms rather than three. Its moat rests on technical differentiation and switching costs for labs that have standardized workflows around its antibody panels, but it remains a sub-scale player against Thermo Fisher, Agilent, Bio-Rad, and BD, and faces a near-term patent expiration (November 2026) on key legacy mass cytometry IP — making continued innovation and successful execution of its narrower post-divestiture strategy the key determinants of whether its technical niche translates into durable share gains.